Revolutionizing Dementia Research With Synuclein Biomarker Tests

Neurology Live, August 31, 2023

The SYNTap biomarker test (Amprion), first in its class qualitative laboratory developed test, is the only seed amplification assay that is available for helping to diagnosis synucleinopathies including Parkinson disease (PD), Lewy Body dementia (DLB), and Alzheimer disease (AD). Recently, Amprion was contracted by the National Institutes of Health (NIH) Intramural Research Program’s Center for Alzheimer’s and Related Dementias (CARD) to investigate the levels of misfolded alpha-synuclein proteins in patients with AD using data gathered from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)...READ MORE

Please Note: Important Billing Info

To improve patient access to the SYNTap® Biomarker CSF Test, Amprion offers the following billing options:

  • List price of $1500, with courtesy billing for both Medicare and private insurance.
  • An affordable self-pay price of $995 (patients may qualify for financial assistance and/or interest-free payment options).
  • Prices are effective as of January 1, 2024, and are subject to change.

Please note: Amprion is a Medicare participating provider, however, the SYNTap test does not currently have Medicare coverage determination. Also, Amprion is not yet in network with most insurers.

The SYNTap Biomarker CSF Test has been issued a dedicated CPT® PLA code to be used when billing: 0393U.

For additional information, please visit our billing page.